Objective To initially explore the efficacy and safety of programmed cell death protein 1(PD-1)inhibitors in cross-line treatment in patients with advanced gastric cancer.Methods From December 2020 to July 2022,40 advanced gastric cancer patients with disease progression(PD)after previously using sintilimab plus first-line chemotherapy regimen were collected.According to whether they continued to use sintilimab,40 patients were divided into cross-line group(n=21)and non-cross-line group(n=19).Clinical efficacy and treatment-related adverse reactions were compared between both groups.Results All 40 cases in the whole group completed 4 cycles of treatment and were eligible for efficacy evaluation.Among the 21 cases in the cross-line group,there were 1 case of complete response(CR),9 cases of partial response(PR),10 cases of stable disease(SD)and 1 case of PD with the response rate(RR)of 47.62%(10/21)and disease control rate(DCR)of 95.24%(20/21).Among the 19 cases in the non-cross-line group,there were 1 case of CR,5 cases of PR,7 cases of SD and 6 cases of PD with the RR of 31.58%(6/19)and DCR of 68.42%(13/19).The RR between both groups were similar(P=0.301),but the DCR of the cross-line group was higher than that of the non-cross-line group(P=0.040).The medium progression-free survival of the cross-line group and the non-cross-line group were 4.6 months and 4.1 months,and the difference was not statistically significant(P＞0.05).The incidence of grade 3-4 adverse reactions was relatively low,and there was no statistically significant difference in the overall incidence of adverse reactions between both groups(P＞0.05).Conclusion PD-1 inhibitors have good benefits and good safety profile when used as cross-line treatment for patients with advanced gastric cancer.
关键词
晚期胃癌/程序性死亡蛋白1/抑制剂跨线治疗/疗效/安全性
Key words
Advanced gastric cancer/Programmed cell death protein 1 inhibitors/Cross-line therapy/Curative effect/Safety
维普
万方数据